Evidence map›Paper›PMID 41766965›Full record

ArticleFrontiers in public health2025

People living with HIV co-infected with HBV at the Nkembo Outpatient Treatment Center, Gabon: prevalence and associated factors.

Rolf Moukanda-Ifoundou, Rachyda Massolou-Outata, Christian Mangala, Christian Mombo-Maganga, Gwladys Esmeralda Matsomo-Kombet, Josiane Alda Boukandou-Bina, Darly Yenze-Mouelé, Alain Moutsinga, Serge Christian Okolongo-Mayani, Denis Maulot-Bangola and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rolf Moukanda-IfoundouOutpatient Treatment Center of Nkembo, Libreville, Gabon.
Rachyda Massolou-OutataOutpatient Treatment Center of Nkembo, Libreville, Gabon.
Christian MangalaCatholic University of Central Africa, Yaoundé, Cameroon.
Christian Mombo-MagangaCatholic University of Central Africa, Yaoundé, Cameroon.
Gwladys Esmeralda Matsomo-KombetCatholic University of Central Africa, Yaoundé, Cameroon.
Josiane Alda Boukandou-BinaCatholic University of Central Africa, Yaoundé, Cameroon.
Darly Yenze-MoueléNational Public Health Laboratory, Libreville, Gabon.
Alain MoutsingaCatholic University of Central Africa, Yaoundé, Cameroon.
Serge Christian Okolongo-MayaniCatholic University of Central Africa, Yaoundé, Cameroon.
Denis Maulot-BangolaCatholic University of Central Africa, Yaoundé, Cameroon.
Hervé OuamboCatholic University of Central Africa, Yaoundé, Cameroon.
Joseph FokamCatholic University of Central Africa, Yaoundé, Cameroon.
Brice OngaliDepartment of Cellular and Molecular Biology - Genetics, University of Health Sciences, Libreville, Gabon.
Guy Joseph LemamyDepartment of Cellular and Molecular Biology - Genetics, University of Health Sciences, Libreville, Gabon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatitis B virus (HBV) is a global public health problem that affects many people, including people living with HIV (PLHIV). In Gabon, HBV infection remains a concern among PLHIV. This study aimed to determine the prevalence of HBV and its associated risk factors among PLHIV at the Nkembo Outpatient Treatment Center in Gabon. Methods: This was a cross-sectional study conducted at the Nkembo Outpatient Treatment Center in Gabon from 25 March to 31 May 2024, involving 410 PLHIV. Blood samples (plasma) were collected for analysis. The OnSite HBV-5 Rapid Test was used to detect the HBs antigen and HBe antigen. CD4 + counting was performed using the BD FACSPresto™ system. The measurement of HBV and HIV viral loads was carried out using the QuantStudio™5 device, after performing extraction using GenoXtract® (version 1.0). Statistical analysis of the data was conducted using SPSS (version 21.0). Results: Among the 410 PLHIV, the seroprevalence of HBV was 10.5% (95% CI: 7.9-13.8). Alcohol intake (adjusted odds ratio (aOR) = 2.1, 95% CI:1.2-3.4, Conclusion: The prevalence of HBV remains a concern among PLHIV. Therefore, HBV screening is strongly recommended to improve the management of PLHIV in order to reduce this burden of co-infection.

Indexed as

CoinfectionHepatitis BHIV InfectionsAdultCross-Sectional StudiesFemaleGabonHumansMaleMiddle AgedPrevalenceRisk FactorsViral LoadYoung AdultGabonhepatitis B viruspeople living with HIVprevalencerisk factors

Identifiers

PMID41766965
PMCPMC12935903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.